Literature DB >> 34956612

Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment.

Qiang Wang1, Jing Wang1, Jiayou Wang1, Xiaoli Ju2, Heng Zhang3.   

Abstract

Shikonin is one of the major bioactive components of Lithospermum erythrorhizon. It has a good killing effect in a variety of tumor cells. Its antitumor effect involves multiple targets and pathways and has received extensive attention and study in recent years. In this review, we systematically review recent progress in determining the antitumor mechanism of shikonin and its derivatives, specifically their induction of reactive oxygen species production, inhibition of EGFR and PI3K/AKT signaling pathway activation, inhibition of angiogenesis and induction of apoptosis and necroptosis. We also discuss the application of nanoparticles loaded with shikonin in the targeted therapy of various cancers. Finally, we suggest new strategies for the clinical application of shikonin and its derivatives.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antitumor; apoptosis; nanoparticles; reactive oxygen species; shikonin

Year:  2021        PMID: 34956612      PMCID: PMC8692723          DOI: 10.1093/toxres/tfab107

Source DB:  PubMed          Journal:  Toxicol Res (Camb)        ISSN: 2045-452X            Impact factor:   3.524


  94 in total

1.  Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.

Authors:  J Chen; J Xie; Z Jiang; B Wang; Y Wang; X Hu
Journal:  Oncogene       Date:  2011-04-25       Impact factor: 9.867

Review 2.  From traditional Chinese medicine to rational cancer therapy.

Authors:  Thomas Efferth; Paul C H Li; Venkata S Badireenath Konkimalla; Bernd Kaina
Journal:  Trends Mol Med       Date:  2007-07-17       Impact factor: 11.951

3.  Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis.

Authors:  Weidong Han; Jiansheng Xie; Ling Li; Zhen Liu; Xun Hu
Journal:  Apoptosis       Date:  2009-05       Impact factor: 4.677

Review 4.  Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.

Authors:  T E Taylor; F B Furnari; W K Cavenee
Journal:  Curr Cancer Drug Targets       Date:  2012-03       Impact factor: 3.428

5.  Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.

Authors:  Wen-Xue Sun; Hong-Wei Han; Min-Kai Yang; Zhong-Ling Wen; Yin-Song Wang; Jiang-Yan Fu; Yun-Ting Lu; Ming-Yue Wang; Jia-Xin Bao; Gui-Hua Lu; Jin-Liang Qi; Xiao-Ming Wang; Hong-Yan Lin; Yong-Hua Yang
Journal:  Bioorg Med Chem       Date:  2019-10-15       Impact factor: 3.641

6.  The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway.

Authors:  Mingzhu Liu; Yong Yang; Can Wang; Lidong Sun; Chuanzhong Mei; Wantong Yao; Yonglei Liu; Yinghong Shi; Shuangjian Qiu; Jia Fan; Xiumei Cai; Xiliang Zha
Journal:  Arch Biochem Biophys       Date:  2010-07-27       Impact factor: 4.013

7.  Shikonin protects dopaminergic cell line PC12 against 6-hydroxydopamine-mediated neurotoxicity via both glutathione-dependent and independent pathways and by inhibiting apoptosis.

Authors:  Emran Esmaeilzadeh; Mossa Gardaneh; Ehsan Gharib; Farzaneh Sabouni
Journal:  Neurochem Res       Date:  2013-05-01       Impact factor: 3.996

Review 8.  The role of double-strand break repair - insights from human genetics.

Authors:  Mark O'Driscoll; Penny A Jeggo
Journal:  Nat Rev Genet       Date:  2006-01       Impact factor: 53.242

9.  Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation.

Authors:  Qiqi Zhang; Qing Liu; Shutao Zheng; Tao Liu; Lifei Yang; Xiujuan Han; Xiaomei Lu
Journal:  J Cancer       Date:  2021-06-11       Impact factor: 4.207

10.  The trajectory of gait development in mice.

Authors:  Shyam K Akula; Katherine B McCullough; Claire Weichselbaum; Joseph D Dougherty; Susan E Maloney
Journal:  Brain Behav       Date:  2020-04-24       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.